COVID-19 Update

Combatting Future Viral Threats with Vaccine Advances

The COVID-19 pandemic has led to many changes in how pharmaceutical companies develop vaccines.

What’s Next for COVID-19 Vaccines and Variants?

More technologies and treatments are emerging for COVID-19—along with new variants.

Key Elements for Assay Transfer Success

Partnerships formed during the COVID-19 pandemic have provided a platform for change in assay development and transfers.

Novavax Begins Shipping its COVID-19 Vaccine to European Union Member States

February 23, 2022

Novavax announces the first doses of Nuvaxovid COVID-19 vaccine have begun shipping to European Union member states.

BioNTech Plans to Build Modular mRNA Manufacturing Facilities in Africa

February 21, 2022

The turnkey facilities will promote scalable vaccine production for an end-to-end manufacturing network for mRNA-based vaccines in Africa.

Health Canada Authorizes Novavax COVID-19 Vaccine

February 18, 2022

Health Canada authorizes Novavax COVID-19 vaccine for individuals 18 years of age and older.

Moderna Plans Expansion in Europe

February 18, 2022

The company has announced plans to establish a commercial presence in six European countries.

FDA Grants Eli Lilly Drug EUA for Treatment of COVID-19

February 17, 2022

FDA has granted Eli Lilly and Company’s bebtelovimab, a monoclonal antibody designed for treatment of COVID-19, an Emergency Use Authorization (EUA).

EMA Updates Guidance on Risk Management Plans for COVID-19 Vaccines

February 16, 2022

Guidance published during the pandemic has been updated to include content requirements for summary safety reports.

EMA Investigating Reports of Menstrual Irregularities with COVID-19 Vaccines

February 16, 2022

The agency’s safety committee is assessing reported cases of period irregularities associated with Comirnaty and Spikevax mRNA vaccines.

EMA Considers Adolescent Booster-Dose Application for Comirnaty

February 11, 2022

EMA has started its evaluation of an application for the use of a booster dose of Comirnaty in adolescents aged 12–15 years.

What’s Next for COVID-19 Vaccines and Variants?

February 03, 2022

Although mRNA and viral vector vaccines have been top of mind for COVID-19 treatments, other technologies and treatments are emerging—along with new variants.

Global Vaccine Access Challenges FDA and Industry

February 02, 2022

The global nature of the COVID-19 pandemic emphasizes the critical importance of expanded vaccination.